ATE334993T1 - Hydratformen des natriumsalzes von alendronat, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese enthalten - Google Patents

Hydratformen des natriumsalzes von alendronat, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese enthalten

Info

Publication number: ATE334993T1
Authority: AT; Austria
Prior art keywords: pharmaceutical compositions; alendronate; production; sodium salt; compositions containing
Prior art date: 1998-08-27

Application number

AT99944004T

Other languages

English (en)

Inventor

Nina Finkelstein

Ramy Lidor-Hadas

Judith Aronhime

Original Assignee

Teva Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-27

Filing date

1999-08-27

Publication date

2006-08-15

1999-08-27 Application filed by Teva Pharma filed Critical Teva Pharma

2006-08-15 Application granted granted Critical

2006-08-15 Publication of ATE334993T1 publication Critical patent/ATE334993T1/de

Links

OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 title abstract 4
238000004519 manufacturing process Methods 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 3
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
229940062527 alendronate Drugs 0.000 title 1
NOJNFULGOQGBKB-UHFFFAOYSA-M sodium;3-[3-tert-butylsulfanyl-1-[[4-(6-ethoxypyridin-3-yl)phenyl]methyl]-5-[(5-methylpyridin-2-yl)methoxy]indol-2-yl]-2,2-dimethylpropanoate Chemical compound [Na+].C1=NC(OCC)=CC=C1C(C=C1)=CC=C1CN1C2=CC=C(OCC=3N=CC(C)=CC=3)C=C2C(SC(C)(C)C)=C1CC(C)(C)C([O-])=O NOJNFULGOQGBKB-UHFFFAOYSA-M 0.000 title 1
229960004343 alendronic acid Drugs 0.000 abstract 3
208000006386 Bone Resorption Diseases 0.000 abstract 1
208000020084 Bone disease Diseases 0.000 abstract 1
230000024279 bone resorption Effects 0.000 abstract 1
238000010348 incorporation Methods 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Physical Education & Sports Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Orthopedic Medicine & Surgery (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Rheumatology (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

AT99944004T 1998-08-27 1999-08-27 Hydratformen des natriumsalzes von alendronat, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese enthalten ATE334993T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US9831398P	1998-08-27	1998-08-27
US12974399P	1999-04-16	1999-04-16
US14446199P	1999-07-19	1999-07-19

Publications (1)

Publication Number	Publication Date
ATE334993T1 true ATE334993T1 (de)	2006-08-15

Family

ID=27378576

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99944004T ATE334993T1 (de)	1998-08-27	1999-08-27	Hydratformen des natriumsalzes von alendronat, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese enthalten

Country Status (30)

Country	Link
US (2)	US6281381B1 (de)
EP (1)	EP1107974B1 (de)
JP (2)	JP2002523514A (de)
KR (2)	KR20070034132A (de)
AT (1)	ATE334993T1 (de)
AU (1)	AU5698899A (de)
BG (1)	BG65329B1 (de)
BR (1)	BR9913472A (de)
CA (1)	CA2341459A1 (de)
CZ (1)	CZ2001629A3 (de)
DE (1)	DE69932620T2 (de)
DK (1)	DK1107974T3 (de)
EA (1)	EA002739B1 (de)
EE (1)	EE04552B1 (de)
ES (1)	ES2270613T3 (de)
HR (1)	HRP20010129A2 (de)
HU (1)	HUP0203078A3 (de)
IL (1)	IL141423A (de)
IS (1)	IS5864A (de)
LT (1)	LT4888B (de)
LV (1)	LV12720B (de)
NO (1)	NO20010957L (de)
NZ (1)	NZ510682A (de)
PL (1)	PL346347A1 (de)
PT (1)	PT1107974E (de)
RO (1)	RO122854B1 (de)
SI (1)	SI20581B (de)
SK (1)	SK2482001A3 (de)
WO (1)	WO2000012517A1 (de)
YU (1)	YU14701A (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2336312T3 (es) *	2001-07-16	2010-04-12	Universite Paris 13	Procedimiento de preparacion de derivados de bisfosfonatos.
GB2383042A (en)	2001-10-18	2003-06-18	Cipla Ltd	Amorphous alendronate sodium
US20040052843A1 (en) *	2001-12-24	2004-03-18	Lerner E. Itzhak	Controlled release dosage forms
KR100897837B1 (ko) *	2001-12-24	2009-05-15	테바 파마슈티컬 인더스트리즈 리미티드	분말 또는 과립 물질의 압착된 환상체 내에 싸인 활성성분의 코어 정제를 갖는 제형과, 이의 제조 방법 및 툴링
ITMI20020146A1 (it) *	2002-01-29	2003-07-29	Lyogen Ltd	Alendronato monosodico amorfo e processo per la sua preparazione
CA2480814A1 (en) *	2002-04-05	2003-10-23	Merck & Co., Inc.	Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20080249068A1 (en) *	2002-09-05	2008-10-09	Deluca Hector F	Method of Extending the Dose Range of Vitamin D Compounds
WO2005035542A1 (en) *	2003-10-14	2005-04-21	Pliva-Istrazivanje I Razvoj D.O.O.	Solid-state form of alendronate sodium and preparation thereof
US20050181043A1 (en) *	2004-02-12	2005-08-18	Indranil Nandi	Alendronate salt tablet compositions
US20050261250A1 (en) *	2004-05-19	2005-11-24	Merck & Co., Inc.,	Compositions and methods for inhibiting bone resorption
NZ551118A (en)	2004-05-24	2010-09-30	Warner Chilcott Co Llc	Enteric solid oral dosage form of bisphosphonate containing a chelating agent
CZ296937B6 (cs) *	2004-09-02	2006-07-12	Zentiva, A. S	Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
AR052321A1 (es) *	2004-10-29	2007-03-14	Sandoz Ag	Procesos para la preparacion de un polipeptido
US20060134190A1 (en) *	2004-12-16	2006-06-22	Banner Pharmacaps Inc.	Formulations of bisphosphonate drugs with improved bioavailability
CZ297262B6 (cs) *	2004-12-28	2006-10-11	Zentiva, A. S.	Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
US8003820B2 (en) *	2005-10-20	2011-08-23	Dr. Reddy's Laboratories Limited	Process for preparing bisphosphonic acids
AR058168A1 (es) *	2005-11-07	2008-01-23	Merck & Co Inc	Sintesis del alendronato de sodio trihidratado
CA2667345C (en) *	2006-10-27	2016-03-22	Signal Pharmaceuticals, Llc	Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith
JP5244608B2 (ja) *	2006-11-22	2013-07-24	エーザイ・アール・アンド・ディー・マネジメント株式会社	二糖類化合物のナトリウム塩及びその製造方法並びにその使用
US20090076144A1 (en) *	2007-09-17	2009-03-19	Protia, Llc	Deuterium-enriched bazedoxifene
US20090118238A1 (en) *	2007-09-17	2009-05-07	Protia, Llc	Deuterium-enriched alendronate
US20090170815A1 (en) *	2007-12-28	2009-07-02	Roxane Laboratories Incorporated.	Alendronate oral liquid formulations
CN102040644B (zh) *	2009-11-03	2014-05-14	刘力	丹参酮衍生物及其制备和用途
MY180626A (en)	2013-11-15	2020-12-03	Akebia Therapeutics Inc	Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3016289A1 (de)	1980-04-28	1981-10-29	Henkel KGaA, 4000 Düsseldorf	Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) *	1982-04-15	1989-01-27	Gentili Ist Spa	Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) *	1984-08-06	1987-01-27	Ciba-Geigy Corporation	Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) *	1984-09-21	1986-04-03	Henkel KGaA, 4000 Düsseldorf	4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) *	1984-10-29	1988-11-16	Gentili Ist Spa	Procedimento per la preparazione di acidi difosfonici
US4711800A (en) *	1985-06-06	1987-12-08	Divincenzo Maureen	Needlecraft with metallic substrate
US4922007A (en) *	1989-06-09	1990-05-01	Merck & Co., Inc.	Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) *	1990-06-20	1991-05-28	Merck & Co., Inc.	Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5039819A (en)	1990-09-18	1991-08-13	Merck & Co., Inc.	Diphosphonate intermediate for preparing an antihypercalcemic agent
US5159108A (en)	1990-09-18	1992-10-27	Merck & Co., Inc.	Process for preparing an antihypercalcemic agent
EP0837863A4 (de)	1995-06-06	1999-06-16	Merck & Co Inc	Dinatriumalendronat-formulierungen
ATE289199T1 (de) *	1995-06-06	2005-03-15	Merck & Co Inc	Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten

1999
- 1999-08-27 WO PCT/US1999/019838 patent/WO2000012517A1/en not_active Ceased
- 1999-08-27 CA CA002341459A patent/CA2341459A1/en not_active Abandoned
- 1999-08-27 EE EEP200100126A patent/EE04552B1/xx not_active IP Right Cessation
- 1999-08-27 ES ES99944004T patent/ES2270613T3/es not_active Expired - Lifetime
- 1999-08-27 DK DK99944004T patent/DK1107974T3/da active
- 1999-08-27 BR BR9913472-1A patent/BR9913472A/pt not_active Application Discontinuation
- 1999-08-27 EA EA200100184A patent/EA002739B1/ru not_active IP Right Cessation
- 1999-08-27 NZ NZ510682A patent/NZ510682A/en not_active IP Right Cessation
- 1999-08-27 HR HR20010129A patent/HRP20010129A2/hr not_active Application Discontinuation
- 1999-08-27 RO ROA200100219A patent/RO122854B1/ro unknown
- 1999-08-27 CZ CZ2001629A patent/CZ2001629A3/cs unknown
- 1999-08-27 PT PT99944004T patent/PT1107974E/pt unknown
- 1999-08-27 AT AT99944004T patent/ATE334993T1/de not_active IP Right Cessation
- 1999-08-27 JP JP2000567539A patent/JP2002523514A/ja not_active Withdrawn
- 1999-08-27 SK SK248-2001A patent/SK2482001A3/sk unknown
- 1999-08-27 AU AU56988/99A patent/AU5698899A/en not_active Abandoned
- 1999-08-27 KR KR1020077004456A patent/KR20070034132A/ko not_active Ceased
- 1999-08-27 US US09/384,145 patent/US6281381B1/en not_active Expired - Fee Related
- 1999-08-27 EP EP99944004A patent/EP1107974B1/de not_active Expired - Lifetime
- 1999-08-27 IL IL14142399A patent/IL141423A/xx not_active IP Right Cessation
- 1999-08-27 YU YU14701A patent/YU14701A/sh unknown
- 1999-08-27 KR KR1020017002535A patent/KR20010079701A/ko not_active Ceased
- 1999-08-27 PL PL99346347A patent/PL346347A1/xx not_active Application Discontinuation
- 1999-08-27 SI SI9920070A patent/SI20581B/sl not_active IP Right Cessation
- 1999-08-27 HU HU0203078A patent/HUP0203078A3/hu unknown
- 1999-08-27 DE DE69932620T patent/DE69932620T2/de not_active Expired - Fee Related
2001
- 2001-02-26 LT LT2001016A patent/LT4888B/lt not_active IP Right Cessation
- 2001-02-26 BG BG105292A patent/BG65329B1/bg unknown
- 2001-02-26 IS IS5864A patent/IS5864A/is unknown
- 2001-02-26 NO NO20010957A patent/NO20010957L/no not_active Application Discontinuation
- 2001-04-05 LV LVP-01-26A patent/LV12720B/en unknown
- 2001-07-03 US US09/898,756 patent/US6696601B2/en not_active Expired - Fee Related
2009
- 2009-02-18 JP JP2009035788A patent/JP2009143955A/ja active Pending

Also Published As

Publication number	Publication date
NO20010957L (no)	2001-04-26
EE04552B1 (et)	2005-10-17
DE69932620T2 (de)	2006-12-14
JP2009143955A (ja)	2009-07-02
LT4888B (lt)	2002-02-25
IL141423A0 (en)	2002-03-10
US20030065214A1 (en)	2003-04-03
LT2001016A (en)	2001-10-25
JP2002523514A (ja)	2002-07-30
IS5864A (is)	2001-02-26
KR20010079701A (ko)	2001-08-22
PT1107974E (pt)	2006-10-31
ES2270613T3 (es)	2007-04-01
WO2000012517A1 (en)	2000-03-09
BG105292A (en)	2001-12-29
YU14701A (sh)	2003-01-31
NZ510682A (en)	2003-09-26
EE200100126A (et)	2002-06-17
LV12720A (lv)	2001-09-20
EA200100184A1 (ru)	2001-10-22
IL141423A (en)	2005-09-25
BR9913472A (pt)	2002-03-05
WO2000012517A9 (en)	2000-07-13
EA002739B1 (ru)	2002-08-29
US6281381B1 (en)	2001-08-28
PL346347A1 (en)	2002-02-11
EP1107974A4 (de)	2001-09-26
CZ2001629A3 (cs)	2001-08-15
SI20581A (sl)	2001-12-31
NO20010957D0 (no)	2001-02-26
HUP0203078A3 (en)	2005-01-28
AU5698899A (en)	2000-03-21
BG65329B1 (bg)	2008-02-29
KR20070034132A (ko)	2007-03-27
HRP20010129A2 (en)	2005-04-30
DE69932620D1 (de)	2006-09-14
EP1107974A1 (de)	2001-06-20
US6696601B2 (en)	2004-02-24
SK2482001A3 (en)	2002-01-07
DK1107974T3 (da)	2006-10-30
LV12720B (en)	2002-02-20
CA2341459A1 (en)	2000-03-09
HUP0203078A2 (hu)	2003-01-28
EP1107974B1 (de)	2006-08-02
RO122854B1 (ro)	2010-03-30
SI20581B (sl)	2008-06-30

Legal Events

Date

Code

Title

Description

2007-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1107974

Country of ref document: EP

2010-05-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE334993T1 (de)	2006-08-15	Hydratformen des natriumsalzes von alendronat, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese enthalten
CA2337991A1 (en)	2000-01-27	Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents
ZA953469B (en)	1996-01-17	New compound
FR2780403B3 (fr)	2000-07-21	Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
NO995006D0 (no)	1999-10-14	Nye forbindelser
DE69513167D1 (de)	1999-12-09	Perfluoroalkyll ketone, inhibitoren von elastase und prozess zur deren herstellung
CA2415354A1 (en)	2002-01-31	Phospholipid derivatives of valproic acid and mixtures thereof
PT1051159E (pt)	2002-09-30	Composicoes farmaceuticas solidas contendo miltefosina para administracao oral no tratamento de leishmaniose
BG105275A (en)	2001-11-30	Tan-1057 derivatives
SI0748795T1 (en)	2001-02-28	Substituted benzyloxycarbonyl guanidines as Na+/H+ exchange inhibitors, process for their preparation, their use as medicinal or diagnostic agents as well as medicament containing them
DE59807096D1 (de)	2003-03-06	Verfahren zur herstellung von fludarabin-phosphat-lithium-, natrium-, kalium-, calcium- und magnesium-salzen, reinigungsverfahren zur herstellung von fludarabin-phosphat und fludarabin-phosphat mit mindestens 99,5 %iger reinheit
FR2665374B1 (fr)	1992-12-04	Microcapsules a paroi mixte d'atelocollagene et de polyholosides coagulee par un cation bivalent et procede de fabrication de ces microcapsules et des compositions cosmetiques ou pharmaceutiques ou alimentaires en contenant.
ATE205473T1 (de)	2001-09-15	Neue borneolderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
ES2137665T3 (es)	1999-12-16	Nuevos derivados de piridina o piridazina, procedimientos para su preparacion, y medicamentos que contienen estos compuestos.
HUP9904564A3 (en)	2001-01-29	Substituted aminomethyl-cycloheptenes, process for producing them, their use, and pharmaceutical compositions containing them
DE59606000D1 (de)	2000-11-23	Verfahren zur Herstellung von 2-Phosphonobutan-1,2,4-tricarbonsäure und ihrer Alkalimetallsalze
EP1702924A3 (de)	2007-07-18	Hydratformen des Natriumsalzes von Alendronat, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen
IL110025A0 (en)	1994-10-07	Phosphonosuccinic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
RU2003117876A (ru)	2004-12-27	Фармацевтическая композиция для лечения воспалительных процессов в заднем отрезке глаза "делипос"
MXPA04000953A (es)	2004-04-20	Derivados sustituidos del acido 5,6,6a,11b-tetrahidro-7-oxa-aza-benzo[c]fluoren-6-carboxilico como antagonista de nmda.
ZA200104651B (en)	2002-08-28	Use of substituted 4-biarylbutyric 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases.